Parse Biosciences' Evercode v4 Boosts Single-Cell Sequencing Scalability
Event summary
- Parse Biosciences, a QIAGEN company, launched Evercode Whole Transcriptome v4, a new single-cell RNA sequencing product line.
- Evercode v4 supports up to 5 million cells and 384 samples per run, significantly increasing scalability.
- The new workflow utilizes magnetic beads, replacing centrifugation and increasing cell recovery by up to 75%.
- Evercode v4 eliminates off-target reads, improving gene detection and reducing sequencing costs.
- Shipping is scheduled to begin in March 2026.
The big picture
The single-cell sequencing market is experiencing rapid growth, driven by advancements in genomics and personalized medicine. Parse Biosciences' Evercode v4 aims to address key bottlenecks in the workflow – scalability, cost, and cell recovery – positioning it to capture a larger share of this expanding market. The acquisition by QIAGEN suggests a strategic move to integrate single-cell sequencing capabilities into a broader portfolio of molecular biology solutions.
What we're watching
- Adoption Rate
- The success of Evercode v4 will hinge on its adoption by research institutions and biotech companies, particularly given the upfront investment required for new workflows.
- Competitive Response
- Competitors in the single-cell sequencing market will likely respond with their own advancements, potentially eroding Parse's market share if v4's advantages aren't substantial and defensible.
- Integration
- The effectiveness of Parse’s integration with QIAGEN’s broader Sample to Insight solutions will be crucial for maximizing value and driving further adoption of the Evercode platform.
Related topics